Causaly vs Harvey AI (2026)

Causaly

by Causaly

Harvey AI

by Harvey

Pros

• ✓Proprietary biomedical knowledge graph of 500 million facts and 70 million directional relationships provides evidence depth that general-purpose AI platforms cannot replicate, enabling R&D teams to trace every output to its source with full scientific provenance.
• ✓Documented productivity outcomes at pharmaceutical scale: ProQR achieved 5x productivity over PubMed for target identification (February 2025) and a top 10 global life sciences company cut proposal time by 75% during a disease area transition (April 2026).
• ✓Agentic AI agents purpose-built for pharmaceutical R&D use cases: target identification, drug repositioning, mechanism of action investigation, and safety assessment. Outputs carry traceable logic designed to withstand scientific and regulatory scrutiny.

Limitations

• –Enterprise-only pricing with no self-serve tier excludes academic researchers, individual scientists, and small biotech startups: the platform requires a sales-led annual contract with no trial access, no freemium option, and no public pricing.
• –Implementation complexity requires sustained life sciences expertise: knowledge graph configuration, AI agent setup for R&D workflows, integration with proprietary pharmaceutical databases, and R&D team rollout are all required before the platform delivers value.
• –Specialized exclusively for life sciences with no cross-domain research value: teams evaluating general-purpose alternatives will find Gemini Deep Research ($19.99/mo) or ChatGPT Deep Research ($20/mo) substantially more cost-effective outside pharma R&D workflows.

Pros

• ✓Harvey Agents execute complex legal work end to end: from contract analysis and due diligence through drafting and research, agents plan the work, split large tasks across parallel agents, and return cited, review-ready output without step-by-step attorney direction. Scheduled Agents can also run recurring work in the background.
• ✓Deep enterprise adoption and backing: Harvey states that more than 200,000 professionals at over 2,400 law firms and in-house legal teams use it, named clients include Dentons, KKR, Bridgewater, PwC, Deutsche Telekom, and Procter and Gamble, and it raised $550M at a $15.5B valuation in September 2026.
• ✓Works where legal teams already work: iManage, NetDocuments, SharePoint, Google Drive and Box connections, Word and Outlook add-ins, LexisNexis research content, and MCP in both directions, with a first-party MCP server for outside assistants and MCP connectors that pull in PitchBook, Datasite and SS&C Intralinks data.

Limitations

• –Enterprise-only pricing with no public price list and no self-serve plan, so every deployment starts with a sales conversation and buyers cannot compare cost before a demo. Spellbook and CoCounsel ($360/mo billed annually) are the closest alternatives for teams that want to compare.
• –Harvey publishes no setup or implementation timeline and offers no self-serve trial, so firms cannot switch it on and evaluate it on their own before engaging Harvey sales. Its MCP connectors to outside tools launched in early access, and Harvey describes MCP governance as a shared responsibility with the firm admins who choose which tool actions are permitted.
• –Independent review volume is small relative to adoption: the G2 and Gartner Peer Insights corpora each hold well under fifty reviews despite more than 200,000 professionals using the platform, so procurement teams relying on review sites will find thin public evidence.